Preoperative adjuvant GP chemotherapy regimen vs DP chemotherapy regimen in the treatment of non -small cell lung cancer
10.13699/j.cnki.1001-6821.2014.10.024
- VernacularTitle:多西他赛对比吉西他滨联合顺铂方案治疗非小细胞肺癌临床疗效
- Author:
Feng-Jun PAN
1
;
Wei-Qiang TIAN
;
Xiao-Fen WU
;
Guang-Mao YU
;
Wei-Jun FANG
Author Information
1. 浙江省丽水市中心医院
- Keywords:
preoperative adjuvant chemotherapy;
GP chemotherapy regiment;
non -small cell lung carcinoma
- From:
The Chinese Journal of Clinical Pharmacology
2014;(10):949-951
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of DP vs GP regimen with preoperative adjuvant chemotherapy on central stage Ⅲ a non -small cell lung cancer (NSCLC).Methods Fifty -eight cases of central stage Ⅲ a NSCLC patients were recruited in this prospective study.All the cases were randomly divided into DP group (n =27) and GP group (n =31).Patients in DP group were treated with 75 mg? m-2 of docetaxel and cisplatin on the first day , 21 days as a cycle.And cases in the GP group received 1000 mg? m 2 of gemcitabine on the first and eighth day as well as 70 mg? m-2 of cisplatin by intravenous infusion on day one, 28 days as a cycle.Patients in both groups received 2 -3 cy-cles adjuvant chemotherapy.Results The objective response rate and operative rate in DP and GP were 44.4% (12 /27)vs 38.7%(12 /31) and 66.7%(18 /27)vs 54.8%(17 /31)respectively, which demonstrated no statistical difference between the two groups were observed .The Ⅲ/Ⅳ hematologic toxicity were 11.1%(3 /27) and 29.0%(9 /31) in DP and GP regimen respectively, which showed it was much higher in GP regimen ( P <0.05) .Conclusion There was no significant clinical efficacy in the DP and GP chemotherapy regimens for the treatment of central stage Ⅲa NSCLC, but there is a lower risk of developing Ⅲ/Ⅳhematologic toxicity in DP regimen.
